Carbohydrate-based synthetic vaccines for HIV
View Patent ↗The present invention relates to a constructed oligosaccharide cluster, optionally bonded to an immunogenic protein, that can be administered to a subject to induce an immune response for increasing production of 2G12 and/or used in assays as reactive sites for determining compounds that inactivate and/or bind the high-mannose oligosaccharide cluster. Compositions comprising these clusters, methods of using these clusters and compositions are disclosed.
1. A high-mannose oligosacoharide cluster that mimics a carbohydrate epitope on gp120 comprising four high-mannose oligosaccharides positioned on a cyclic core scaffolding framework, wherein the cyclic core scaffolding framework comprises monosaccharides, or cyclic organic compounds, wherein the four high-mannose oligosaccharides are Man 9 , and wherein the positioning of high-mannose oligosaccharides on the cyclic core scaffolding framework mimics the carbohydrate epitope on gp120 having affinity for 2G12 antibodies.
2. The high-mannose oligosaccharide cluster according to claim 1 , further comprising an immunogenic protein conjugated to the high-mannose oligosaccharide cluster thereby producing a high-mannose oligosaccharide/protein cluster.
3. The high-mannose oligosacoharide cluster of claim 2 , wherein the immunogenic protein is selected from the group consisting of keyhole limpet hemocyanin, tetanus toxoid, diphtheria toxoid, bovine serum albumin, ovalbumin, thyroglobulin, myoglobin, cholera toxin β-subunit, immunoglobulin and/or tuberculosis purified protein derivative.
4. The high-mannose oligosaccharide cluster of claim 2 comprising four Man 9 covalently attached to a galactose scaffolding framework, wherein the immunogenic protein comprises keyhole limpet hemocyanin.
5. A pharmaceutical composition comprising the high-mannose oligosaccharide cluster of claim 1 .
6. A method for generating a high-mannose oligosaccharide cluster, the method comprising:
covalently attaching four high-mannose oligosaccharide chain to a cyclic core scaffolding framework, wherein the cyclic core scaffolding framework comprises monosaccharides, or cyclic organic compounds, wherein the four high-mannose oligosaccharides are Man 9 , and wherein the positioning of high-mannose oligosaccharides on the cyclic core scaffolding framework mimics a carbohydrate epitope on gp120 having affinity for 2G12 antibodies.
7. The method according to claim 6 , wherein the high-mannose oligosaccharide chain is extracted from the digestion of soybean agglutinin or produced by chemical synthesis.
8. The method of claim 6 , further comprising conjugating an immunogenic protein to the high-mannose oligosaccharide cluster.
9. A method of inducing production of HIV antibodies that exhibit affinity for a conserved cluster of oligomannose sugars on gp120, the method comprising:
administering to an animal the high-mannose oligosaccharide according to claim 2 in an amount sufficient to induce production of antisera specific for the high-mannose oligosaccharide; and collecting the antisera.
10. A method for detecting candidate compounds that potentially interact with a conserved cluster of oligomannose sugars on gp120, the process comprising:
contacting the candidate compound with the high-mannose oligosaccharide cluster according to claim 1 ; and
determining the binding affinity of the candidate compound for high-mannose oligosaccharide cluster.